EPISODE · Mar 24, 2023 · 3 MIN
News Explained: Why did the Indian Patent Office reject J&J’s application to extend its patent on an anti-TB drug?
from BusinessLine Podcasts · host BusinessLine
The Indian Patents Office on Thursday rejected an application of global pharma major Johnson and Johnson seeking an extension of its patent on anti-Tuberculosis (TB) drug Bedaquiline beyond July 2023, when it is set to expire. Why is this significant? Will it help TB patients in India? The Hindu businessline's Senior Deputy Editor G Naga Sridhar explains in this episode of News Explained. Tune in to know more. --- Send in a voice message: https://podcasters.spotify.com/pod/show/business-line/message
Embed this episode
NOW PLAYING
News Explained: Why did the Indian Patent Office reject J&J’s application to extend its patent on an anti-TB drug?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.